Feasibility of AI as First Reader in the 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Impact on Negative-Misclassifications and Clinical Referral Rate

Authors
Anna N H Walstr, Harriet L Lancaster, Marjolein A Heuvelmans, Carlijn M van der Aalst, Juul Hubert, Dana Moldovanu, Sytse F Oudkerk, Daiwei Han, Jan Willem C Gratama, Mario Silva, Harry J de Koning, Matthijs Oudkerk
Journal
European Journal of Cancer
Related Product

LCS

Date Published
2024.12
Summary

The paper published by iDNA evaluates the feasibility of using AI software (AVIEW-LCS) as a first reader in the 4-IN-THE-LUNG-RUN trial. This study compared the performance of AI and radiologists in identifying negative cases and their impact on clinical referral rates. Among 3,678 participants, AI recorded 31 (0.8%) negative misclassifications (NM), outperforming radiologists, who recorded 407 (11.1%) NMs. Additionally, the NM referral rate for AI was significantly lower at 2.9%, compared to 11.8% for radiologists. AI demonstrated the potential to reduce workload by 71.2% while maintaining diagnostic safety. The study highlights AI’s potential to improve diagnostic workflows and alleviate radiologists’ burden. Here, NM refers to false-negative classifications at the first reading, while NM referral represents false-negative classifications at the final review. The paper also discusses positive misclassification (PM), noting that AI's PM rate (5.7%) was higher than that of radiologists (0.5%). However, it concludes that the additional burden from AI’s PM is minimal while emphasizing the need for further research.

Contact

제품, 인재 채용, 투자 관련 또는 기타 문의사항이 있으신 경우 편하신 방법으로 연락주시기 바랍니다

문의하기